share_log

欧盟有条件批准葛兰素史克收购辉瑞消费者健康业务

EU conditionally approves GlaxoSmithKline's acquisition of Pfizer's consumer health business

道琼斯 ·  Jul 11, 2019 16:54

EU antitrust regulators conditionally approved the acquisition of Pfizer Inc., PFE's consumer health business by Glaxosmithkline PLC, GSK, GSK.LN on Wednesday night.

The approval depends on the sale of Pfizer's ThermaCare business, which makes products that manage local pain.

The initial form of the deal would have reduced competition in the local pain management product industry and could have led to higher prices in several European countries, including Germany, Italy and the Netherlands.

The European Commission said the assets must be divested as a whole to a suitable buyer in order to be approved by the commission.

The European Commission also said that the sale of the business almost completely eliminated the overlap between the two companies' activities in this area.

By Pietro Lombardi; Write to Pietro Lombardi at pietro.lombardi@dowjones.com


Copyright (c) 2019 Dow Jones Co., Ltd. The copyright of this article belongs to Dow Jones and may not be translated or reproduced without permission.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment